Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.62 |
| ▸ | CNR2 | P34972 | 7/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL277784 | 0.88 | CNR1 (0.62) | CNR1CNR2PTGS2PTGS1 | |
| Hydrochloric Acid SCHEMBL278149 | 0.87 | CNR1 (0.61) | CNR1CNR2PTGS2PTGS1 | |
| SCHEMBL29838955 | 0.83 | CYP1A2 (0.57) | CNR1CNR2PTGS2 | |
| SCHEMBL16197705 | 0.83 | CNR1 (0.57) | CNR1CNR2PTGS2 | |
| SCHEMBL4187519 | 0.82 | CA1 (0.58) | CNR1CNR2PTGS2PTGS1 | |
| SCHEMBL276817 | 0.82 | CNR2 (0.76) | CNR1CNR2 | |
| SCHEMBL16197630 | 0.80 | CNR1 (0.57) | CNR1CNR2 | |
| SCHEMBL277080 | 0.79 | CNR1 (0.54) | CNR1CNR2PTGS2PTGS1 | |
| SCHEMBL4885515 | 0.79 | RPA1 (0.57) | CNR1CNR2PTGS2 | |
| SCHEMBL6341478 | 0.79 | PTGS2 (0.79) | CNR1PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133904-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity | JENRIN DISCOVERY, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| EP-2182807-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | Jenrin Discovery (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009033125-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20090069329-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069329-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | CNR2, CNR1, GPR119 | CNR1 2/4885CNR2 1/4885PTGS2 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.